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Abstract
The syntheses of silica-supported oligomeric benzyl phosphates (Si-OBPn) and triazole 
phosphates (Si-OTPn) using ring-opening metathesis polymerization (ROMP) for use as efficient 
alkylating reagents is reported. Ease of synthesis and grafting onto the surface of norbornenyl-
tagged (Nb-tagged) silica particles has been demonstrated for benzyl phosphate and triazole 
phosphate monomers. It is shown that these silica polymer hybrid reagents, Si-OBPn and Si-OTPn, 
can be used to carry out alkylation reactions with an array of different nucleophiles to afford the 
corresponding benzylated and (triazolyl)methylated products in good yield and high purity.
Graphical abstract
INTRODUCTION
The need to rapidly synthesize a wide variety of small molecules in the desired quantities 
with high purities and yields is an important challenge facing drug discovery and 
developmental chemistry. 1 To help address this need, immobilized reagents and scavengers 
have been developed to provide ease of synthesis and to eliminate time-consuming 
chromatographic separation protocols. These reagents have found frequent use in the arena 
of facilitated synthesis and high-throughput chemistry, 2, 3 as well as in the scale-up of 
advanced pharmaceutical intermediates.4 Given the large range of chemistries and 
conditions in which they need to be employed as reagents, scavengers, or catalysts, the field 
has seen a number of new innovations regarding immobilized polystyrene resins, 5 silicas, 6 
*Corresponding Author: phanson@ku.edu.
Notes
The corresponding author (PRH) is a member of the Scientific Advisory Board at Materia, Inc.
†Materia, Inc. 60 N. San Gabriel Blvd. Pasadena, CA 91107.
ASSOCIATED CONTENT
Supporting Information. Experimental details and NMR spectral data for new compounds. This material is available free of charge via 
the Internet at http://pubs.acs.org
HHS Public Access
Author manuscript
J Org Chem. Author manuscript; available in PMC 2016 October 16.
Published in final edited form as:













soluble polyethylene glycol (PEG) polymers,7 monolith8 and fluorous-tagged compounds9 
to remove impurities or excess reagents from reaction mixtures. Some of the more recent 
developments reported include silica-supported isocyanide ligands for scavenging 
ruthenium,10 mesocellular silica-supported boronic acids as direct amidation catalysts, 11 
silica-supported rhodium catalysts, 12 N-heterocyclic carbenes, 13 palladium and copper (I) 
catalysts,14 phosphines,15, prolinol and TADDOLs.16 However, for all of their advantages 
immobilized reagents are often limited by several factors, including (i) low load levels (ii) 
heterogeneous reaction kinetics and non-surface diffusion-controlled processes, (iii) 
immobilized reagent swelling, and (iv) poor solvent tolerance. While some of these issues 
have been addressed through the development of technologies such as microgels, Janda-gels 
and micro-porous resins,3 there is still a need for additional materials that can deliver the 
performance of solution-phase reagents with the ease of removal (via filtration, precipitation, 
extraction, etc.) afforded by their immobilization.
We have previously examined a variety of soluble, high-load, oligomeric reagents and 
scavengers derived through the use of ring-opening methathesis polymerization (ROMP) of 
functionalized norbornene and 7-oxanorbornene monomers. 17 These materials, known as 
ROMPgels, build on the pioneering efforts of Barrett,18 Buchmeiser,19 Bolm20 and others;21 
and they have effectively been used to mediate a number of chemical reactions. However, 
while these ROMPgel materials have the advantage of behaving equivalently to traditional 
homogeneous reagents and catalysts, they are generally removed from solution via 
precipitation, which can limit their use in pharmaceutical applications.
As a result, inspired by the seminal work of Buchmeister and coworkers, 22 efforts were 
focused on the synthesis and study of a number of hybrid materials that graft several of the 
ROMPgel materials onto the surface of silica particles.23 Through this grafting process, the 
resulting immobilized ROMP reagents can be removed from solution by simple filtration, 
thus eliminating the precipitation step. In this fashion, silica-supported ROMPgel acid 
chloride, dichlorotriazine, and triphenylphosphine reagents were generated with properties 
nearly identical to the equivalent soluble ROMPgel oligomeric reagents.23
We herein describe our efforts to expand the family oligomeric materials that have been 
grafted onto silica to include ROMP-derived oligomeric benzyl phosphate (OBPn) and 
triazole phosphate (OTPn), which we previously reported as soluble alkylating reagents that 
were used in facilitated library generation.24 Benzylation and triazolation are useful 
diversification reactions in medicinal chemistry, high-throughput chemistry, and diversity-
oriented synthesis (DOS).25 The benzylation of amines and alcohols also serves as one of 
the most utilized protecting group strategies in organic synthesis due to its easy 
incorporation and removal.26 While these uses have spurred development of a number of 
alternative approaches to benzylation27 and triazolation, we believe the generation of the 
analogous silica-oligomeric benzyl phosphate (Si-OBPn) and triazole phosphate (Si-OTPn) 
reagents could find efficient, safe, and cost effective applications in chemical synthesis and 
library production. Key advantages of these reagents, include: (i) their stability at room 
temperature (ii) safety in handling when compared to commercially available benzyl 
bromides or iodides, and (iii) ease of purification via simple filtration through Celite®.
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Initial efforts centered on the synthesis of the silica-grafted oligomeric benzyl phosphate 
reagent, as outlined in Scheme 1, using a modification of the procedure reported by 
Buchmeiser.28 The activated silica 1 (60 Å, 20 μm) was tagged with commercially available 
norbornene silyl reagent [(MeO)3Si-(CH2)2-Nb (2)] followed by capping with 
trimethoxymethylsilane and dimethoxydimethylsilane to afford the norbornene-
functionalized silica (Si-Nb) 3 (Scheme 1). It was observed that, the use of (MeO)3Si-
(CH2)2-Nb (2) dramatically increased the norbornene load of Si-Nb (3), compare to 5-
(bicycloheptenyl)-triethoxysilane [Nb-Si(OEt)3], which was previously used for silica 
tagging.23 By this optimized method, we prepared norbornene-functionalized silica 3 (Si-
Nb) on gram scale with 0.4 mmol/g loading (determined by modified bromine titration 
method).29 With this Si-tagged nanoparticle (3) in hand, a metathesis catalyst-armed 
surface-initiated polymerization was established using the C848 [Grubbs 2nd generation 
catalyst, G-II)30 (20 mol%, based on Si-Nb load) in CH2Cl2 and toluene as solvents, 
followed by addition of the Nb-tagged benzyl phosphate monomer 4 to rapidly generate the 
desired hybrid material 5a, silica oligomeric benzyl phosphate (Si-OBPn). The benzyl 
phosphate monomer 4 was itself easily synthesized in good yield and purity according to 
previously reported methods.24a Norbornene exo-diol 6 was reacted with POCl3 and Et3N in 
the presence of catalytic DMAP to generate the Nb-tagged monochlorophosphate compound 
7 in moderate yields as a white solid (Scheme 1). This material was then reacted with benzyl 
alcohol in NMI, and CH2Cl2 at room temperature to yield 4. The scale-up synthesis of the 
monomeric reagent, as well as Si-OBPn have been carried out on gram scale as stable, free-
flowing powders. The SEM images of Si-OBPn and Si-OTPn silica hybrid materials 
demonstrate the grafting of the corresponding monomer on silica surface and inherent 
morphology of hybrid materials (Figure 1).
The utilization of silica oligomeric benzyl phosphate 5a (Si-OBPn) for benzylation with 
various N-, O-, S- nucleophiles including anilines, amines, phenols, thiols, and sulfonamides 
(Table 1), were next examined. The reactions were carried out in a sealed pressure tube with 
different nucleophiles (1 equiv.), Si-OBPn (1.5 equiv), Cs2CO3 (3.0 equiv.) and NaI (0.2 
equiv.) in THF at 80 °C (oil bath temperature) to yield the products after simple filtration via 
Celite®-SPE to remove Si-phosphate by-product. The corresponding benzylated analogs 
(8a–8h) were isolated in excellent purities (>90%, determined by LC-MS) and yields. We 
have screened wide varieties of nucleophile for benzylation. Initially, a variety of amines and 
phenols (Table 1, entry 1–4) were utilized and then extended to thiophenols and 
sulfonamides (Table 1, entry 5–8) to yield (>90%) of the benzylated products.
With these results in hand, an expanded set of Si-OBPn derivatives was next examined 
(Figure 2). These high load reagents (5b–5d) were synthesized in an analogous fashion to 
the Si-OBPn reagent in Scheme 1 and were also obtained on gram scales as free-flowing 
powders. Utilization of these reagents in substitution reaction with O- and S-nucleophiles 
were next carried out to afford benzylated products (8i–8n) in good yield (>90%) and 
excellent purity after Celite®-SPE filtration (Table 2). Diversification of the Si-OBPn 
reagents via substituting electron withdrawing groups, as well as electron donating groups, 
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on the aryl moiety were next examined, and in all cases, analogous results to Table 1 were 
obtained (see Table 2).
Attention was next placed on the gram-scale generation of silica oligomeric triazole 
phosphate hybrid reagents (Si-OTPn). Triazoles and their derivatives have demonstrated a 
wide variety of biological activity, with many reports focusing on antifungal activity.31 We 
previously reported soluble oligomeric triazole phosphates to construct a wide array of 
triazole-containing compounds. Silica-immobilized oligomeric triazole phosphate 10a (Si-
OTPn) was synthesized via grafting of the Nb-tagged benzyl triazole phosphate monomer 9 
onto the surface of norbornene-functionalized silica (Si-Nb) 3 through the same protocol 
discussed for the synthesis of Si-OBPn in Scheme 1. The product, 10a (Si-OTPn), was 
isolated as a free flowing solid in high-load (1.15 mmol/g) (Scheme 2). The triazole 
phosphate monomer 9 was synthesized in good yield and purity according to previously 
reported methods.24 Phosphorylation of propargyl alcohol with Nb-tagged phosphonyl 
chloride 7, followed by a “Click”-capture event of the corresponding azide, yields the 
desired monomer 9 in an efficient fashion (Scheme 2). The triazole phosphate monomer, as 
well as silica oligomeric triazole phosphate reagents (Si-OTPn) have been synthesized on 
gram scale as stable, free-flowing solids.
With Si-OTPn 10a in hand, the hybrid material was evaluated for (triazolyl)methylation on 
various nucleophiles including amines, phenols, thiophenols and sulfonamides in good 
yields and high purity with chromatography-free purification. The reaction was carried out 
in a pressure tube with different nucleophiles (1 equiv.), Si-OTPn (1.5 equiv.), Cs2CO3 (3.0 
equiv.) and NaI (0.2 equiv.) in DMF at 90 °C for overnight. The reaction mixture was diluted 
with EtOAc and filtered through a pad of Celite® to give the corresponding 
(triazolyl)methylated products. Optimal results were achieved in DMF compared to THF. A 
variety of N-, O-, S-nucleophiles were utilized for nucleophilic substitution reaction with Si-
OTPn triazolating reagent gave the (triazolyl)methylated products (11a–11g) in excellent 
yield and high purity (>85%, determined by LC-MS) (Table 3). In all cases, similar results 
(Table 3) were obtained as compared to Si-OBPn in THF in Table 1.
Building on these results, the project was expanded to the synthesis of additional variants of 
Si-OTPn hybrid reagents (10b–10d, Figure 3) on gram scales as free-flowing powders in an 
analogous fashion to the Si-OTPn reagent in Scheme 2. These Si-OTPn hybrid reagents were 
utilized for (triazolyl)methylation of O- and S-nucleophiles. In all cases, 
(triazolyl)methylated products (11h–11m) were isolated in excellent yield and high purity 
after passing thru a Celite® SPE (Table 4).
In conclusion, the combination of Nb-tagged silica particles and functionalized Nb-tagged 
monomers efficiently yields high-load, hybrid Si-ROMP benzylating and 
(triazolyl)methylating reagents. A metathesis catalyst-armed surface (CAS)-initiated 
polymerization was key to functionalization of units off the silica particle surface. With this 
technology, we developed Si-immobilized oligomeric benzyl phosphate (Si-OBPn) as a 
benzylating reagent and triazole phosphate (Si-OTPn) as a (triazolyl)methylating reagent on 
gram scale as stable, free-flowing powders in all cases, utilizing ROMP of Nb-tagged 
phosphate monomers. SEM imaging was utilized to demonstrate the successful grafting of 
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the corresponding oligomer and the inherent morphology of the hybrid materials. Utilization 
of these reagents for representative small molecule synthesis, under purification free 
protocols, was demonstrated to afford corresponding products in excellent yield and with 
high purity. Since benzylation is a key transformation in many synthetic processes, we are 
currently working on expanding the scope of nucleophiles (i.e., alcohols, bis-nucleophilic, 
etc), as well as the scale on which these transformations can be carried out.
EXPERIMENTAL SECTION
General Information
All reactions were carried out under argon atmosphere. Stirring was achieved with oven-
dried magnetic stir bars. Et2O and CH2Cl2 were purified by passage through the Solv-Tek 
purification system employing activated Al2O3 (Pangborn, A. B.; Giardello, M. A.; Grubbs, 
R. H.; Rosen, R. K.; Timmers, F. J. Safe and Convenient Procedure for Solvent Purification 
Organometallics 1996, 15, 1518–1520). CHCl3 was passed through basic alumina and dried 
over molecular sieves. Et3N was purified by passage through basic alumina or distilled over 
CaH2 and stored over KOH. For Celite-SPE 6 mL empty cartridges were used. All the 
solvents for routine isolation of products and chromatography were reagent grade. Flash 
chromatography was performed using silica gel (300–400 mesh) with the indicated solvents. 
Melting points were recorded on an Electrothermal digital melting point apparatus and were 
uncorrected. IR spectra were recorded on a spectrophotometer using KBr optics. 1H NMR 
and 13C NMR spectra were recorded on 400 or 500 MHz (1H NMR) and 100 or 125 MHz 
(13C NMR) spectrometers using CDCl3 as the solvent and TMS as the internal standard. 
The 1H NMR data are reported as the chemical shift in parts per million, multiplicity (s, 
singlet; d, doublet; t, triplet; q, quartet; m, multiplet), coupling constant in hertz, and number 
of protons. High-resolution mass spectra were obtained using a high-resolution ESI-TOF 
mass spectrometer.
General Procedure for Silica Oligomeric Benzyl Phosphate (Si-OBPn) and Triazole 
Phosphate (Si-OTPn)
Si-Nb (load ~0.4 mmol/g, 1 equiv.) was heated with C848 (G-II, 0.2 equiv.) at 45 °C in 
dichloromethane for 2 hrs under argon. The OBP or OTP monomer was added (50 equiv. w/r 
to cat. G-II) in CH2Cl2 and toluene to the reaction mixture and heated at 45 °C for 
overnight. The reaction mixture was cooled to room temperature and EVE was added, with 
stirring for an additional 1 hour at room temperature. The reaction mixture was filtered and 
washed with mixture of toluene:CH2Cl2 (1:1), and dried over high vacuo pump.
Procedure A: General procedure for different nucleophilic substitution with Si-OBPn
In a sealed pressure tube was added Si-OBPn 5a (1.5 equiv.), followed by addition of sodium 
iodide (0.2 equiv.), Cs2CO3 (3.0 equiv.), and solvent THF (0.2M). The mixture was stirred 
rapidly and then nucleophiles were added. The reaction was sealed under argon and heated 
to 80 °C with stirring for 12 h. After such time, the reaction was cooled to rt and the crude 
mixture was filtered via a Celite®-packed SPE and rinsed several times with a mixture of 
hexanes:EtOAc (1:2). The resulting eluent was concentrated in vacuo to yield the benzylated 
products in good to excellent yields and purities.
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Procedure B: General procedure for different nucleophilic substitution with Si-OTPn
In a pressure tube was added Si-OTPn 10a (1.5 equiv.), followed by addition of NaI (0.2 
equiv.), Cs2CO3 (3.0 equiv.), and solvent DMF (0.2M). The nucleophile was added and the 
resulting mixture was stirred rapidly. The reaction was sealed under argon and heated to 
90 °C w/ stirring for (12–14 hrs) after which time, DMF was removed in vacuo. The crude 
mixture was filtered via celite®-SPE and rinsed with EtOAc. The resulting eluent was then 
concentrated in vacuo to yield the products in good to excellent yields and purities.
1-(benzyloxy)-4-(tert-butyl)benzene (8c)
Utilizing general procedure A, 8c (18.5 mg, 0.077 mmol, 97%) was isolated as a white solid. 
MP: 65 °C; FTIR (neat): 3056, 3024, 2960, 2866, 1610, 1512, 1456, 1242, 1182, 1024 
cm−1; 1H NMR (400 MHz, CDCl3): δ7.46–7.43 (m, 2H), 7.42–7.38 (m, 2H), 7.36–7.30 (m, 
3H), 6.92–6.96 (m, 2H), 5.06 (s, 2H), 1.33 (s, 9H); 13C NMR (126 MHz, CDCl3): δ 156.6, 
143.7, 137.3, 128.5 (2C), 127.9, 127.5 (2C), 126.2 (2C), 114.2 (2C), 70.0, 34.1, 31.4 (3C); 
GC-MS (EI+) calculated for C17H20O 240.15; found 240.1 (M+ 7), 91.0 (100).32a
1-(benzyloxy)-2,4-dichlorobenzene (8d)
Utilizing general procedure A, 8d (30 mg, 0.119 mmol, 98%) was isolated as a thick liquid. 
FTIR (neat): 3031, 2931, 2835, 1597, 1481, 1452, 1382, 1290, 1249, 1060 cm−1; 1H NMR 
(400 MHz, CDCl3): δ 7.47–7.44 (m, 2H), 7.43–7.38 (m, 3H), 7.37–7.33 (m, 1H), 7.18 (dd, J 
= 2.6, 8.7 Hz, 1H), 6.90 (d, J = 8.9 Hz, 1H), 5.16 (s, 2H); 13C NMR (126 MHz, CDCl3): δ 
153.0, 136.1, 130.1, 128.7 (2C), 128.1, 127.5, 127.1 (2C), 126.0, 124.1, 114.8, 71.2; GC-MS 
(EI+) C13H10Cl2O calculated 252.01; found 251.9 (M+ 4), 91.0 (100).32b
Benzyl(2,4,6-trichlorophenyl)sulfane (8e)
Utilizing general procedure A, 8e (21 mg, 0.07 mmol, 98%) was isolated as a yellow solid. 
MP: 112 °C; FTIR (neat): 3087, 2935, 2850, 1583, 1454, 1321, 1116, 1054 cm−1. 1H NMR 
(400 MHz, CDCl3): δ 7.47 (s, 1H), 7.37–7.33 (m, 4H), 7.32–7.39 (m, 2H), 4.15 (s, 2H); 13C 
NMR (126 MHz, CDCl3): δ 136.3, 135.3, 132.0, 131.3, 130.6, 130.0, 129.5, 128.9 (2C), 
128.8 (2C), 127.8, 37.6; GC-MS (EI+) C13H9Cl3S calculated 301.95; found 301.9 (32), 169 
(7), 91.0 (100).
Benzyl(3,4-dimethoxyphenyl)sulfane (8f)
Utilizing general procedure A, 8f (22 mg, 0.085 mmol, 98%) was isolated as a thick liquid. 
FTIR (neat): 2933, 2833, 1595, 1504, 1251, 1228, 1135, 1026 cm−1. 1H NMR (400 MHz, 
CDCl3): δ 7.31 –7.19 (m, 5H), 6.95 (dd, J = 8.3, 2.2 Hz, 1H), 6.0–6.74 (m, 2H), 4.02 (s, 2H), 
3.88 (s, 3H), 3.75 (s, 3H); 13C NMR (126 MHz, CDCl3): δ 148.7 (2C), 138.2, 129.0 (2C), 
128.4 (2C), 127.0, 126.2, 125.3, 115.9, 111.3, 55.9, 55.8, 41.2; GC-MS (EI+) C15H16O2S 
calculated 260.09; found 260.0 (32), 169 (30), 91.0 (100).
N-benzyl-4-bromo-N-butyl-2-fluorobenzenesulfonamide (8g)
Utilizing general procedure A, 8g (24 mg, 0.060 mmol, 99%) was isolated as a thick liquid. 
FTIR (neat): 3089, 3025, 2958, 2931, 1589, 1472, 1456, 1396, 1344, 1161, 1135 cm−1. 1H 
NMR (500 MHz, CDCl3): δ 7.79 (t, J = 7.70 Hz, 1H), 7.43–7.38 (m, 2H), 7.34–7.28 (m, 
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5H), 4.47 (s, 2H), 3.19 (t, J = 7.60 Hz, 2H), 1.35–1.29 (m, 2H), 1.16–1.11 (m, 2H), 0.76 (t, J 
= 7.45 Hz, 3H). 13C NMR (126 MHz, CDCl3): δ 158.44 (1JC–F = 259 Hz), 136.1, 131.8, 
128.6 (2C), 128.2 (2C), 128.0, 127.8 (3C), 120.7 (2J = 25.0 Hz), 51.4, 47.3, 29.7, 19.7, 13.5. 
GC-MS (EI+) C17H19BrFNO2S calculated 399.3; found 399.0 (M+ 3), 401.2 (M+2 2), 355.8 
(60), 357.8 (60), 91 (100).
(S)-2,3-dibenzyl-7-bromo-3,4-dihydro-2H-benzo[b][1,4,5]oxathiazepine1,1-dioxide (8h)
Utilizing general procedure A, 8h (30 mg, 0.066 mmol, 97%) was isolated as a white solid. 
MP: 170 °C. FTIR (neat): 3026, 2921, 2852, 1595, 1552, 1325, 1153, 700 cm−1. 1H NMR 
(500 MHz, CDCl3): δ 7.74 (d, J = 8.5 Hz, 1H), 7.33–7.28 (m, 4H), 7.25–7.19 (m, 5H), 7.17 
(d, J = 1.8 Hz, 1H), 6.92 (d, J = 7.5 Hz, 2H), 4.85 (t, J = 12.0 Hz, 1H), 4.40 (d, J = 14.3 Hz, 
1H), 4.26 (dd, J = 4.5, 13.42 Hz, 1H), 4.09 (d, J = 14.6 Hz, 1H), 3.85 (m, 1H), 2.93 (m, 
2H). 13C NMR (126 MHz, CDCl3): δ 156.1, 137.4, 135.2, 129.8, 130.8, 129.0 (2), 128.7 (2), 
128.6 (2), 128.1 (2), 127.1 (2), 126.7, 126.4, 124.4, 73.7, 62.4, 55.2, 37.9. HRMS calculated 
for C22H20BrNO3SNa (M+Na)+ 480.0245; found 480.0258 (TOF MS).
1-((4-bromobenzyl)oxy)-2,4-dichlorobenzene (8i)
Utilizing general procedure A, 8i (29 mg, 0.088 mmol, 98%) was isolated as a yellow solid. 
MP: 87 °C. FTIR (neat) 3070, 2923, 2866, 1585, 1571, 1480, 1456, 1290, 1262, 1103 
cm−1. 1H NMR (500 MHz, CDCl3): δ 7.52–7.54 (m, J = 8.4 Hz, 2H), 7.40 (d, J = 2.7 Hz, 
1H), 7.32–7.34 (m, 2H), 7.15–7.18 (dd, J = 8.6, 2.4 Hz, 1H), 6.85 (d, J = 8.8, 1H), 5.10 (s, 
2H). 13C NMR (126 MHz, CDCl3): δ 152.7, 135.0, 131.8 (2C), 130.1, 128.7 (2C), 127.5, 
126.3, 124.1, 122.1, 114.7, 70.3. GC-MS (EI+) C13H9BrCl2O calculated 329.92; found 
331.9 (M+2, 2), 169 (100), 90 (25). 32b
(4-bromobenzyl)(2,4,6-trichlorophenyl)sulfane (8j)
Utilizing general procedure A, 8j (25 mg, 0.066 mmol, 94%) was isolated as a white solid. 
MP: 54 °C. FTIR (neat) 2923, 1590, 1487, 1452, 1433, 1323, 1116, 1058, 1012 cm−1. 1H 
NMR (500 MHz, CDCl3): δ 7.44–7.47 (m, 3H), 7.27 (s, 1H), 7.20–7.22 (m, 2H), 4.08 (s, 
2H). 13C NMR (126 MHz, CDCl3): δ 135.6, 134.5, 132.4, 131.9 (2C), 131.4, 130.7, 130.5 
(2C), 130.4, 129.9, 121.7, 37.1. GC-MS (EI+) C13H8Cl3BrS calculated 379.86; found 379.8 
(M+ 5), 381.8 (M+2, 7), 169 (100), 90 (25).
2,4-dichloro-1-((4-fluorobenzyl)oxy)benzene (8k)
Utilizing general procedure A, 8k (24 mg, 0.088 mmol, 96%) is isolated as a thick liquid. 
FTIR (neat) 2931, 1604, 1510, 1483, 1379, 1226, 1060, 823, 730 cm−1. 1H NMR (500 MHz, 
CDCl3): δ 7.41–7.45 (m, 2H), 7.40 (d, J = 2.5 Hz, 1H), 7.15–7.18 (dd, J = 8.6, 2.5 Hz, 1H), 
7.07–7.11 (m, 2H), 6.88 (d, J = 7.5, 1H), 5.10 (s, 2H). 13C NMR (126 MHz, CDCl3): δ 
162.5 (1JC–F = 246.5 Hz) 152.8, 131.8, 130.1, 129.1 (3J = 8.4 Hz, 2), 127.5, 126.6, 124.2, 
115.6 (2J = 21.6 Hz, 2) 114.9, 70.5. GC-MS (EI+) C13H9Cl2FO calculated 270.00; found 
269.9 (M+ 2), 109 (100).
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Utilizing general procedure A, 8l (21 mg, 0.065 mmol, 95%) was isolated as a thick liquid. 
FTIR (neat) 2933, 1600, 1505, 1433, 1323, 1228, 1116, 1058, 837 cm−1. 1H NMR (500 
MHz, CDCl3): δ 7.49 (s, 1H), 7.31–7.34 (m, 2H), 7.29 (s, 1H), 7.01–7.05 (m, 2H), 4.13 (s, 
2H). 13C NMR (126 MHz, CDCl3): δ 163.3, (1JC–F = 247.5 Hz) 135.8, 132.3, 131.3, 131.1 
(4JC–F = 3.6 Hz), 130.7, 130.5 (3J = 8.5 Hz, 2) 130.4, 129.9, 115.7 (2J = 22.3 Hz, 2), 36.9. 
GC-MS (EI+). C13H8Cl3FS calculated 319.94; found 319.9 (M+ 5), 109 (100).
2,4-dichloro-1-((3,5-dimethoxybenzyl)oxy)benzene (8m)
Utilizing general procedure A, 8m (28 mg, 0.089 mmol, 98%) was isolated as a yellow 
solid. MP: 55 °C; FTIR (neat): 2935, 2825, 1598, 1483, 1456, 1292, 1157, 1060 cm−1; 1H 
NMR (500 MHz, CDCl3): δ 7.38 (d, J = 2.5 Hz, 1H), 7.14–7.16 (dd, J = 8.7, 2.4 Hz, 1H), 
6.88–6.85 (d, J = 7.8 Hz, 1H), 6.60 (d, J = 2.2 Hz, 2H), 6.42 (t, J = 2.5 Hz, 1H), 5.09 (s, 1H), 
3.80 (s, 6H); 13C NMR (126 MHz, CDCl3): δ 161.0 (2C), 152.9, 138.5, 130.0, 127.5, 126.1, 
124.0, 114.8, 104.7 (2C), 99.8, 70.9, 55.3 (2C). GC-MS (EI+). C15H13Cl3O2S, calculated 
312.03; found 312.0 (M+, 3), 151.1 (100).
(3,5-dimethoxybenzyl)(2,4,6-trichlorophenyl)sulfane (8n)
Utilizing general procedure A, 8n (20 mg, 0.055 mmol, 94%) was isolated as a white solid. 
MP: 84 °C; FTIR (neat): 2956, 2931, 2830, 1610, 1596, 1454, 1431, 1323, 1205, 1157, 1158 
cm−1; 1H NMR (500 MHz, CDCl3): δ 7.46 (s, 1H), 7.30 (s, 1H), 6.51 (d, J = 2.25 Hz, 2H), 
6.38 (t, J = 2.3, Hz 1H), 4.08 (s, 2H), 3.79 (s, 6H). 13C NMR (126 MHz, CDCl3): δ 160.1 
(2C), 137.5, 136.3, 131.9, 131.3, 130.6, 130.0, 129.4, 106.9 (2C), 99.8, 55.4 (2C), 37.8. GC-
MS (EI+). C15H13Cl3O2S, calculated 361.97 found 361.9 (M+ 3), 151.1 (100).
1-benzyl-4-((3-chlorophenoxy)methyl)-1H-1,2,3-triazole (11a)
Utilizing general procedure B, 1-benzyl-4-((3-chlorophenoxy)methyl)-1H-1,2,3-triazole 11a 
( 50 mg, 0.167 mmol, 91%) was isolated as a white solid. MP: 96 °C; FTIR (neat): 2960, 
2358, 1610, 1511, 1463, 1250, 1184, 1031 cm-1; 1H NMR (400 MHz, CDCl3): δ 7.53 (s, 
1H), 7.43 – 7.35 (m, 3H), 7.29 (dd, J = 4.8, 2.8 Hz, 2H), 7.20 (t, J = 8.1 Hz, 1H), 6.98 – 6.93 
(m, 2H), 6.89 – 6.84 (m, 1H), 5.55 (s, 2H), 5.17 (s, 2H). 13C NMR (126 MHz, CDCl3): δ 
158.9, 144.1, 134.9, 134.4, 130.3, 129.2 (2C), 128.9, 128.2 (2C), 122.7, 121.5, 115.4, 113.1, 
62.2, 54.3. HRMS calculated for C16H15ClN3O (M+H)+ 300.0904; found 300.0906 (TOF 
MS ES+).
1-benzyl-4-((naphthalen-1-yloxy)methyl)-1H-1,2,3-triazole (11b)
Utilizing general procedure B, 11b (53 mg, 0.168 mmol, 90%) was isolated as a light brown 
solid. MP: 94 °C; FTIR (neat): 3409, 2918, 1583, 1458, 1390, 1267, 1238, 1155, 1095 
cm-1; 1H NMR (400 MHz, CDCl3): δ 8.23 (d, J = 8.1 Hz, 1H), 7.82 (d, J = 7.6 Hz, 1H), 7.62 
(s, 1H), 7.54–7.44 (m, 3H), 7.43–7.36 (m, 4H), 7.34 – 7.25 (m, 2H), 6.98 (d, J = 7.6 Hz, 
1H), 5.57 (s, 2H), 5.41 (s, 2H). 13C NMR (126 MHz, CDCl3): δ 153.9, 144.8, 134.5, 129.2 
(2C), 128.8, 128.1 (2C), 127.5, 126.5, 125.8, 125.6, 125.3, 122.6, 122.0, 120.9, 105.4, 62.5, 
54.3. HRMS calculated for C20H18N3O (M+H)+ 316.1450; found 316.1427 (TOF MS ES+).
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Utilizing general procedure B, 11c (48 mg, 0.198 mmol, 84%) was isolated as a light brown 
thick liquid. FTIR (neat): 3307, 2923, 1581, 1448, 1420, 1396, 1238, 1215, 1121, 1008 
cm-1; 1H NMR (400 MHz, CDCl3): δ 7.59 (s, 1H), 7.41–7.33 (m, 3H), 7.30–7.26 (m, 2H), 
5.52 (s, 2H), 3.87 (s, 2H), 2.74–2.67 (m, 4H), 1.89–1.81 (m, 4H). 13C NMR (126 MHz, 
CDCl3): δ 144.6, 134.6, 129.1 (2C), 128.7, 128.1 (2C), 122.9, 54.2, 53.9 (2C), 50.5, 23.4 
(2C). HRMS calculated for C14H19N4 (M+H)+ 243.1610; found 243.1631 (TOF MS ES+).
1-benzyl-4-(((2,4,6-trichlorophenyl)thio)methyl)-1H-1,2,3-triazole (11e)
Utilizing general procedure B, 11e (63 mg, 0.164 mmol, 92%) was isolated as a white solid. 
MP: 137 °C; FTIR (neat): 3369, 2923, 1699, 1456, 1433, 1363, 1242, 1116, 1049, 721 
cm-1; 1H NMR (400 MHz, CDCl3): δ 7.44 (s, 1H), 7.41–7.34 (m, 5H), 7.24–7.20 (m, 2H), 
5.52 (s, 2H), 4.25 (s, 2H). 13C NMR (126 MHz, CDCl3): δ 143.8, 135.1, 134.4, 132.3, 
131.5, 130.7, 130.6, 130.0, 129.2 (2C), 128.9, 128.0 (2C), 122.1, 54.3, 27.8. HRMS 
calculated for C16H13Cl3N3S (M+H)+ 383.9896; found 383.9912 (TOF MS ES+).
1-benzyl-4-(((3,4-dimethoxyphenyl)thio)methyl)-1H-1,2,3-triazole (11f)
Utilizing general procedure B, 11f (53 mg, 0.155 mmol, 94%) was isolated as a white solid. 
MP: 101 °C; FTIR (neat): 2952, 1581, 1502, 1438, 1253, 1228, 1135, 1024 cm-1; 1H NMR 
(400 MHz, CDCl3): δ 7.58–7.32 (m, 3H), 7.20 (dd, J = 6.7, 2.7 Hz, 2H), 7.17 (s, 1H), 6.89 
(dt, J = 5.1, 2.1 Hz, 2H), 6.72 (d, J = 8.2 Hz, 1H), 5.47 (s, 2H), 4.14 (s, 2H), 3.86 (s, 3H), 
3.79 (s, 3H). 13C NMR (126 MHz, CDCl3): δ 149.0, 148.7, 145.5, 134.6, 129.1 (2C), 128.7, 
127.9 (2C), 125.7, 124.8, 121.9, 115.2, 111.4, 55.9, 55.9, 54.1, 30.8. HRMS calculated for 
C18H19N3O2S (M+Na)+ 364.1096; found 364.1063 (TOF MS ES+).
N-((1-benzyl-1H-1,2,3-triazol-4-yl)methyl)-2-bromo-N-isopropylbenzenesulfonamide (11g)
Utilizing general procedure B, 11g (47 mg, 0.104 mmol, 89%) was isolated as a colorless 
thick liquid. FTIR (neat): 3134, 2923, 2846, 1703, 1604, 1487, 1456, 1411, 1328, 1220, 
1049 cm-1; 1H NMR (400 MHz, CDCl3): δ 8.14 (dd, J = 7.8, 1.8 Hz, 1H), 7.70, (dd, J = 7.7, 
1.4 Hz, 1H), 7.65 (s, 1H), 7.48 – 7.32 (m, 5H), 7.27 – 7.20 (m, 2H), 5.52 (d, J = 5.1 Hz, 2H), 
4.71 (s, 2H), 4.03 – 3.82 (m, 1H), 1.09 (d, J = 6.8 Hz, 6H). 13C NMR (126 MHz, CDCl3): δ 
147.1, 139.3, 135.6, 134.7, 133.5, 132.5, 129.1 (2C), 128.7, 127.9 (2C), 127.5, 123.6, 120.3, 
54.2, 49.9, 38.6, 21.1 (2C). HRMS calculated for C19H21BrN4NaO2S (M+H)+ 471.0466; 
found 471.0478 (TOF MS ES+)
4-((4-bromophenoxy)methyl)-1-(4-methylbenzyl)-1H-1,2,3-triazole (11h)
Utilizing general procedure B, 11h (52 mg, 0.145 mmol, 85%) was isolated as a white solid. 
MP: 103 °C; FTIR (neat): 3087, 2920, 1589, 1490, 1384, 1282, 1242, 1022, 825, 757 
cm−1. 1H NMR (400 MHz, CDCl3): δ 7.49 (s, 1H), 7.37 (d, J = 8.8 Hz, 2H), 7.19 (m, 4H), 
6.85 (d, J = 8.8 Hz, 2H), 5.49 (s, 1H), 5.14 (s, 1H), 2.36 (s, 1H). 13C NMR (126 MHz, 
CDCl3): δ 157.3, 144.1, 138.8, 132.3 (2C), 131.3, 129.8 (2C), 128.2 (2C), 122.6, 116.6 (2C), 
113.5, 62.2, 54.1, 21.2. HRMS calculated for C17H17BrN3O (M+H)+ 358.0555; found 
358.0558 (TOF MS ES+).
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Utilizing general procedure B, 11i (48 mg, 0.120 mmol, 87%) was isolated as a white solid. 
MP: 136 °C; FTIR (neat): 3083, 2920, 1515, 1434, 1323, 1151, 1116, 1058, 871 cm−1. 1H 
NMR (400 MHz, CDCl3): δ 7.43 (s, 1H), 7.38 (s, 1H), 7.31 (s, 1H), 7.18 (d, J = 7.9 Hz, 2H), 
7.12 (d, J = 8.0 Hz, 2H), 5.45 (s, 2H), 4.23 (s, 2H), 2.36 (s, 3H). 13C NMR (126 MHz, 
CDCl3): δ 143.7, 138.2, 135.1, 132.3, 131.5, 131.3, 130.7, 130.5, 130.0, 129.8 (2C), 128.0 
(2C), 122.0, 54.1, 27.9, 21.2. HRMS calculated for C17H15Cl3N3S (M+H)+ 398.0052; found 
398.0063 (TOF MS ES+).
4-((4-bromophenoxy)methyl)-1-(4-methoxybenzyl)-1H-1,2,3-triazole (11j)
Utilizing general procedure B, 11j ( 67 mg, 0.179 mmol, 89%) was isolated as a white solid. 
MP: 98 °C FTIR (neat): 3137, 2933, 1612, 1514, 1487, 1461, 1247, 1176, 1049, 1031, 821 
cm−1. 1H NMR (400 MHz, CDCl3): δ 7.48 (s, 1H), 7.36 (dd, J = 9.6, 2.5 Hz, 2H), 7.23 (d, J 
= 8.6 Hz, 2H), 6.91 (d, J = 8.6 Hz, 2H), 6.85 (d, J = 8.9 Hz, 2H), 5.47 (s, 2H), 5.14 (s, 2H), 
3.82 (s, 3H). 13C NMR (126 MHz, CDCl3): δ 160.0, 157.3, 144.1, 132.3 (2C), 129.8 (2C), 
126.3, 122.4, 116.6 (2C), 114.5 (2C), 113.5, 62.2, 55.4, 53.9. HRMS calculated for 
C17H16BrN3NaO2 (M+Na)+ 396.0324; found 396.0331 (TOF MS ES+).
1-(4-methoxybenzyl)-4-(((2,4,6-trichlorophenyl)thio)methyl)-1H-1,2,3-triazole(11k)
Utilizing general procedure B, 11k ( 50 mg, 0.120 mmol, 86%) was isolated as a yellow 
solid. FTIR (neat): 3082, 2931, 1612, 1514, 1434, 1323, 1249, 1176, 1118, 1058 cm-1; MP: 
88 °C 1H NMR (400 MHz, CDCl3): δ 7.35 (m, 1H), 7.31 (m, 1H), 7.22 (s, 1H), 7.20–7.17 
(m, 1H), 7.09 (dd, J = 8.5, 1.8 Hz, 2H), 6.82 (dd, J = 8.4, 2.1 Hz, 2H), 5.34 (s, 2H), 4.14 (s, 2 
H), 3.74 (s, 3H). 13C NMR (126 MHz, CDCl3): δ 160.0, 143.6, 135.2, 132.3, 131.5, 130.7, 
130.5, 130.0, 129.6 (2C), 126.3, 121.9, 114.5 (2C), 55.4, 53.8, 27.9. HRMS calculated for 
C17H15Cl3N3OS (M+H)+ 414.0001; found 414.0007 (TOF MS ES+).
4-((4-bromophenoxy)methyl)-1-(cyclohexylmethyl)-1H-1,2,3-triazole (11l)
Utilizing general procedure B, 11l (52 mg, 0.148 mmol, 86%) was isolated as a white solid. 
FTIR (neat): 2921, 2852, 1488, 1446, 1384, 1244, 1224, 1112, 1054 cm-1; MP: 90 °C; 1H 
NMR (400 MHz, CDCl3): 7.54 (s, 1H), 7.41–7.35 (ddd, J = 10.2, 3.4, 2.2, 2H), 6.91–6.85 
(ddd, J = 10.2, 3.4, 2.2, 2H), 5.19 (s, 2H), 4.18 (d, J = 7.2 Hz, 2H), 1.94–1.83 (m, 1H), 1.76–
1.61 (m, 5H), 1.29–1.14 (m, 3H), 1.04–0.94 (m, 2H). 13C NMR (126 MHz, CDCl3): δ 157.3, 
143.5, 132.3, 123.1, 116.7, 113.5, 62.3, 56.6, 38.7, 30.5 (2C), 26.0, 25.5 (2C). HRMS 
calculated for C16H21BrN3O (M+H)+ 350.0868; found 350.0870 (TOF MS ES+).
1-(cyclohexylmethyl)-4-(((2,4,6-trichlorophenyl)thio)methyl)-1H-1,2,3-triazole (11m)
Utilizing general procedure B, 11m (48 mg, 0.122 mmol, 88%) was isolated as a white solid. 
FTIR (neat): 2925, 2852, 1450, 1427, 1215, 1153, 1116 cm-1; MP: 141 °C. 1H NMR (500 
MHz, CDCl3): δ 7.46 (s, 1H), 7.39 (d, J = 5.3 Hz, 2H), 4.27 (s, 2H), 4.14 (d, J = 7.2 Hz, 2H), 
1.89–1.79 (m, 1H), 1.76–1.61 (m, 4H), 1.58–1.50 (m, 2H), 1.28–1.09 (m, 4H), 0.95 (qd, J = 
12.2, 3.2 Hz, 2H). 13C NMR (126 MHz, CDCl3): δ 143.1, 135.2, 132.3, 131.5, 130.7, 130.5, 
130.0, 122.6, 56.6, 38.7, 30.4 (2C), 27.8, 26.0, 25.5 (2C). HRMS calculated for 
C16H19Cl3N3S (M+H)+ 390.0365; found 390.0377 (TOF MS ES+).
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SEM images of Si-Nb (left), Si-OBPn (middle) and Si-OTPn (right).
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Various silica-supported Oligomeric Benzyl Phosphate (Si-OBPn) analogs.
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Various silica-supported Oligomeric Triazole Phosphate (Si-OTPn) analogs.
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Synthesis of silica-supported Oligomeric Benzyl Phosphate (Si-OBPn).
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Synthesis of silica-supported Oligomeric Triazole Phosphate (Si-OTPn).
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Table 1
Benzylation of N-, O- and S-nucleophiles utilizing Si-OBPn.
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Table 2
Benzylation of N-, O-and S-nucleophiles utilizing various Si-OBPn analogs.
Entry Si-OBPn Nucleophile Pdt Yield (%)
1 5b 2,4-CI-PhOH 8i 98
2 5b 2,4,6-CI-PhSH 8j 94
3 5C 2,4-CI-PhOH 8k 96
4 5c 2,4,6-CI-PhSH 81 95
5 5d 2,4-CI-PhOH 8m 98
6 5d 2,4,6-CI-PhSH 8n 94
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Table 3
Triazolation utilizing Si-OTPn with O-, N-and S-nucleophiles.
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Table 4
Triazolation of N-, O-and S-nucleophiles utilizing various Si-OTPn Analogs.
Entry Si-OTPn Nucleophile (RB-XH) Pdt Yield (%)
1 10b, R4 = 4-MePh 4-Br-PhOH 11h 85
2 10b, R4 = 4-MePh 2,4,6-CI-PhSH 11i 87
3 10c, R4 = 4-OMePh 4-Br-PhOH 11j 89
4 10c, R4 = 4-OMePh 2,4,6-CI-PhSH 11k 86
5 10d, R4 = cyclohexyl 4-Br-PhOH 111 86
6 10d, R4 = cyclohexyl 2,4,6-CI-PhSH 11m 88
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